Investigating the role of a protein in neurodegenerative diseases like ALS and FTLD.
A novel mouse model of TDP-43 Proteinopathy in FTLD-ALS: Elucidating the role of TDP-43 acetylation in neurodegeneration and proteostasis impairment
This study is looking at how changes to a protein called TDP-43 might play a role in diseases like ALS and frontotemporal lobar degeneration, using a special mouse model to help us understand how this protein affects brain health, which could lead to new treatments for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10857286 on NIH RePORTER |
What this research studies
This research focuses on understanding how the acetylation of the TDP-43 protein contributes to neurodegenerative diseases such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). By using a novel mouse model, the study aims to explore the mechanisms behind TDP-43 aggregation and its impact on neuronal health. The researchers will analyze how this protein's dysfunction affects cellular processes and contributes to disease progression, which could lead to new therapeutic strategies. Patients may benefit from insights gained about the underlying causes of their conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sporadic forms of ALS or FTLD, particularly those without a family history of these diseases.
Not a fit: Patients with familial forms of ALS or FTLD, or those with other unrelated neurodegenerative conditions, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that target the mechanisms of neurodegeneration in ALS and FTLD.
How similar studies have performed: Other research has shown promising results in understanding TDP-43 pathology, but this specific approach using acetylation in a novel mouse model is relatively untested.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Necarsulmer, Julie Christine — Univ of North Carolina Chapel Hill
- Study coordinator: Necarsulmer, Julie Christine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.